BMS, Gilead Atripla Alliance To Include European Commercialization
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck & Co. gives up exclusive ex-U.S. rights to any product containing efavirenz in some European countries to allow the deal.
You may also be interested in...
Gilead Anticipates Lucrative Atripla Launch In EU, Maintains Optimism About Letairis
Detailing its fourth-quarter and full-year 2007 financials, Gilead predicts nine-month rollout for Atripla in five major European nations.
Gilead Anticipates Lucrative Atripla Launch In EU, Maintains Optimism About Letairis
Detailing its fourth-quarter and full-year 2007 financials, Gilead predicts nine-month rollout for Atripla in five major European nations.
Letairis Uptake “Excellent” In First Full Quarter, Gilead Exec Says
Sales of the PAH drug, which competes with Actelion’s Tracleer, were around $6 million, but free-month offer is about to end.